To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.
For more information on this topic, please visit the Real Time Learning Network
*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Topics and Featured Experts:
Johnson & Johnson Vaccine Update
Sara Oliver, MD, MSPH
LCDR, U.S. Public Health Service
Co-Lead, COVID-19 Work Group of the Advisory Committee on Immunization Practices
U.S. Centers for Disease Control and Prevention
Omicron Updates
Update on Current Situation with Omicron
John T. Brooks, MD
Chief Medical Officer
COVID-19 Response
U.S. Centers for Disease Control and Prevention
Re-infection and Omicron
Juliet Pulliam, PhD
Director, South African Center of Excellence in Epidemiological Modelling
and Analysis
Monoclonal Antibody Therapy Updates
Evusheld for Pre-Exposure Prophylaxis in Adults and Children: Update and Clinical Considerations for Use
Cameron R. Wolfe, MBBS (Hons), MPH, FIDSA
Infectious Disease Specialist
Associate Professor of Medicine
Duke University
Bamlanivimab and Etesivimab for Treatment and Post-Exposure Prophylaxis in Pediatric Patients
Sameer J. Patel, MD
Attending Physician, Infectious Disease
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
